N
PRCT icon

Natixis’s Procept Biorobotics PRCT Stock Holding History

Natixis’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,900
Closed -$2.33M – 1140
2025
Q1 		$2.33M Buy
+40,900
New +$2.79M 0.01% 404
2024
Q1 		– Sell
-31,310
Closed -$1.31M – 1178
2023
Q4 		$1.31M Buy
31,310
+30,666
+4,762% +$1.04M 0.01% 476
2023
Q3 		$21.1K Sell
644
-44,258
-99% -$1.51M ﹤0.01% 869
2023
Q2 		$1.56M Sell
44,902
-254
-0.6% -$8.4K 0.01% 468
2023
Q1 		$1.25M Sell
45,156
-47,848
-51% -$1.69M 0.01% 489
2022
Q4 		$3.86M Buy
93,004
+44,832
+93% +$1.93M 0.02% 424
2022
Q3 		$2.03M Buy
48,172
+22,114
+85% +$882K 0.01% 607
2022
Q2 		$862K Buy
+26,058
New +$948K ﹤0.01% 852

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Natixis's PRCT Position: Q2 2025 in Review

Natixis sold out of Procept Biorobotics (PRCT) in Q2 2025, closing a stake of 40,900 shares — an estimated $2.33M sold.

Natixis first reported a position in PRCT in Q2 2022 and held it in 8 quarters. The position peaked at $3.86M in Q4 2022. 271 funds tracked by Wall St. Rank hold PRCT as of Q2 2025.

  • Natixis reported no remaining Procept Biorobotics position as of Q2 2025 after selling out during the quarter.
  • Natixis sold 40,900 Procept Biorobotics shares in Q2 2025, an estimated $2.33M.
  • Natixis first reported a position in Procept Biorobotics in Q2 2022 and held it in 8 quarters.
  • Natixis's Procept Biorobotics position peaked at $3.86M in Q4 2022.
  • 271 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2025.

Based on Natixis's 13F filing for Q2 2025, filed 13 Aug 2025.